




NORRIS
MEDICINES LIMITED



Factory : Plot No. 801/P, 901/3-5, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230GJ1990PLC086581

Date: 12th July, 2017

To,

Mr. Rakesh Parekh,
BSE Limited
Listing Compliance,
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
MUMBAI – 400 001

Sub. : Discrepancies in the Financial Result for the Quarter and year ended March 2017 under Regulation 33 of the SEBI (LODR) Regulations 2015- Norris Medicines Limited (524414)

Ref: Your mail dated 10th July, 2017

Dear Sir,

We refer to your above mentioned mail regarding the discrepancies in the financial results for the quarter and year ended on March, 2017 and would like to resolve the same as under:

Please find enclosed herewith the following:

1. Revised Standalone Audited Financial Results of the Company for the Quarter and Year ended 31st March, 2017.
2. Auditor's Report on the Standalone Audited Financial Results of the Company for the Quarter and Year ended 31st March, 2017.
3. Declaration pursuant to Regulation 33 (3) (d) of (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Kindly take the same on your records and acknowledge the receipt.

Thanking you,

Yours truly,

For, **NORRIS MEDICINES LIMITED**


(VINAY RANA)
COMPANY SECRETARY





NORRIS

MEDICINES LIMITED



Factory : Plot No. 801/P, 901/3-5, GIDC Estate, ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate, ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230GJ1990PLC086581

AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED & YEAR ENDED 31ST MARCH, 2017

Sr. No.	Particulars	(Rs. In Lacs)				
		Quarter ended			Year ended	
		31-03-2017 (Audited)	31-12-2016 (Unaudited)	31-03-2016 (Audited)	31-03-2017 (Audited)	31-03-2016 (Audited)
i	Revenue from Operations	436.98	526.58	515.73	2045.68	1915.31
ii	Other Income	12.38	1.21	-9.28	13.96	0.00
iii	Total Revenue(i+ii)	449.36	527.79	506.45	2059.64	1915.31
iv	Expenses					
	(a) Cost of materials consumed	248.62	262.32	234.11	1052.05	959.36
	(b) Change in inventories of finished goods work in progress and stock-in-trade	-18.46	-36.74	-29.39	-11.97	-29.39
	(c) Employee benefits expense	129.51	145.04	123.63	530.78	483.53
	(d) Finance cost	21.08	14.16	10.63	60.12	67.03
	(e) Depreciation and amortisation expense	21.10	14.50	-34.59	64.60	59.81
	(f) Other Expense	142.90	124.59	114.13	482.36	388.69
	Total Expenses (iv)	544.75	523.87	418.52	2177.94	1929.03
v	Profit / (Loss) before exceptional and extraordinary items and tax (iii-iv)	-95.39	3.92	87.93	-118.30	-13.72
vi	Exceptional items	0.00	0.00	0.00	0.00	0.00
vii	Profit / (Loss) before extraordinary items and tax (v-vi)	-95.39	3.92	87.93	-118.30	-13.72
viii	Extraordinary items	0.00	0.00	0.00	0.00	0.00
ix	Profit / (Loss) before tax (vii-viii)	-95.39	3.92	87.93	-118.30	-13.72
x	Tax Expense					
	(a) Current Tax	0.00	0.00	0.00	0.00	0.00
	(b) Deferred Tax	41.57	0.00	17.50	41.57	17.50
xi	Profit / (Loss) after tax	-53.82	3.92	105.43	-76.73	3.78
xii	Basic and Diluted Earning per equity share	-0.54	0.04	1.05	-0.77	0.04

Notes:

- The above Audited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 29.05.2017.
- The Company is having one segment only and therefore Segmental Reporting is not applicable.
- There are no exceptional/ extraordinary items during the quarter & year ended 31.03.2017.
- Previous year/period figures have been regrouped/rearranged wherever necessary to make them comparable with current period figures.

For, Norris Medicines Limited

Date : 29.05.2017

Place : Chennai



Vimal D. Shah
Managing Director



NORRIS

MEDICINES LIMITED



Factory : Plot No. 801/P, 901/3-5, GIDC Estate, ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate, ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230GJ1990PLC086581

STATEMENT OF ASSETS AND LIABILITIES	31.03.2017 (Audited)	31.03.2016 (Audited)
I. EQUITY AND LIABILITIES		
(1) Shareholder's Funds		
(a) Share Capital	992.57	992.57
(b) Reserves & Surplus	(536.42)	(458.35)
(2) Share Application money pending allotment		
(2) Non - Current Liabilities		
(a) Long Term borrowings	757.00	748.93
(b) Long Term provisions		
(3) Current Liabilities		
(a) Short Term borrowings	370.72	2.31
(b) Trade payables	356.99	253.79
(c) Other current liabilities	196.37	187.02
(d) Short Term provisions	67.15	65.53
TOTAL EQUITY AND LIABILITIES	2204.38	1,791.80
II. ASSETS		
(1) Non -current assets		
(a) Fixed Assets		
(i) Tangible assets	997.14	833.60
(ii) Capital Work in Progress		
(b) Non Current investments	0.88	0.88
(c) Deferred tax assets (net)	181.09	139.52
(d) Long Term Loans and Advances	119.57	137.69
(2) Current Assets		
(a) Current investments		
(b) Inventories	368.90	341.95
(c) Trade Receivables	472.47	277.36
(d) Cash & cash equivalents	4.65	-10.76
(e) Short Term Loans and advances	59.68	71.56
(f) Other Current assets		
TOTAL ASSETS	2,204.38	1,791.80

Date : 29.05.2017
Place : Chennai

For, Norris Medicines Limited



Vimal D. Shah
 Managing Director

Auditor's Report on Quarterly Financial Results and Year to Date Results of Norris Medicines Limited Pursuant to the Regulation 33 of the SEBI (LODR) Regulations, 2015

To,

The Board of Directors
Norris Medicines Limited.

1. We have Audited the Statement of Financial Results of **Norris Medicines Limited** for the quarter ended 31st March, 2017 and the year to date financial year for the period 01.04.2016 to 31.03.2017 ("the financial results"), attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This Statement, which is the responsibility of the company's management and have been prepared on the basis of the related financial statements prepared in accordance with the Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 and other accounting principles generally accepted in India.
2. Our responsibility is to express an opinion on these financial results. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s).

An Audit involves performing procedures to obtain audit evidence, on a test basis, about the amounts and disclosures in the financial results. The Procedures selected depend on the auditor's judgment, including the assessment of the risk of material misstatement of the financial results, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the financial results in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of the accounting policies and the reasonableness of the accounting estimates by the management. We believe that our audit provides reasonable basis for our opinion.



3. In our opinion and to the best of our information and according to the explanations given to us the financial results:
- (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
 - (ii) give a true and fair view in conformity with the aforesaid Accounting Standards and other accounting principles generally accepted in India of the net profit/loss and other financial information of the Company for the year ended 31st March, 2017.
4. The Statement includes the results for the quarter ended 31st March, 2017 being the Balancing figure between audited figures in respect of the full financial year and the year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

Place : BHARUCH
Date : 29.05.2017

232, Rangoli Complex,
Station Road,
Bharuch - 392 001
Gujarat.



For, **MINU MODI & CO.**
Chartered Accountants

A handwritten signature in blue ink, appearing to be "Minu Modi", written over a horizontal line.

CA MINU MODI
Proprietor
M. No. 100289
(Firm Reg. No. 119948W)



NORRIS
MEDICINES LIMITED



Factory : Plot No. 801/P, 901/3-5, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230GJ1990PLC086581

Date: 29th May, 2017

To,

The Manager
Listing Department
The Bombay Stock Exchange Ltd,
Phiroze Jeejeebhoy Towers,
Dalal Street,
MUMBAI - 400 001

Scrip Code: 524414

Sub. : Declaration in respect of Audit Report with an unmodified opinion for the financial year ended 31st March, 2017.

Ref.: Information under Regulation 33 (3) (d) of the SEBI (LODR) Regulation, 2015.

Dear Sir/Madam,

Pursuant to Amendment of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 vide notification dated 25th May, 2016 read with SEBI Circular No. CIR/CFD/CMD/56/2016 dated 27th May, 2016 we hereby declare that the Statutory Auditors, M/s. Minu Modi & Co., Chartered Accountants, Bharuch (Firm Registration No.: 119948W) has submitted the Audit Report for Standalone Financial Results of the Company for the year ended 31st March, 2017 with an unmodified opinion.

Kindly take the above information on your records.

Thanking you,

Yours faithfully,
For **NORRIS MEDICIENS LIMITED**


Vinay Rana
(Company Secretary)

